SPOTLIGHT: GSK allows generic AIDS drug

GlaxoSmithKline says it's letting a Canadian drug company use two of its patented drugs in a combination HIV therapy for Rwanda. Apotex will make the combo--known as Apo-triAvir--using Glaxo's antiretrovirals lamivudine and zidovudine, plus Boehringer Ingelheim's nevirapine. The agreement was struck through Canada's Access to Medicines initiative, a three-year-old bit of legislation intended to help poor countries gain access to needed drugs, but until now has failed to do so. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.